Axcan Eyes Photofrin Gastroenterology Promotion; QLT To Focus on Visudyne
Executive Summary
QLT Phototherapeutics' sale of Photofrin to fellow Canadian firm Axcan will position the product for a potential Barrett's esophagus indication.
You may also be interested in...
Ciba Vision/QLT Visudyne Will Have Average Annual Cost of $4,175/Patient
Ciba Vision/QLT PhotoTherapeutics' Visudyne will have an average cost of $4,175.20 per patient, based on a price to doctors of $1,228 per vial, and an average of 3.4 treatments per patient per year.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials